Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $17,595 | $26,701 |
| General and administrative | 17,565 | 6,590 |
| Total operating expenses | $35,160 | $33,291 |
| Loss from operations | (35,160) | (33,291) |
| Other income (expense): | ||
| Interest income | 3,935 | 805 |
| Change in fair value of warrant liabilities | (188,360) | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's R&D?
- Vor Biopharma (VOR) reported R&D of $17.6M in Q1 2026.
- How has Vor Biopharma's R&D changed year-over-year?
- Vor Biopharma's R&D decreased by 34.1% year-over-year, from $26.7M to $17.6M.
- What is the long-term trend for Vor Biopharma's R&D?
- Over 4 years (2021 to 2025), Vor Biopharma's R&D has grown at a 61.3% compound annual growth rate (CAGR), from $47.53M to $321.53M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Vor Biopharma's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude